JY
WHWK

Jeff Yass’s Whitehawk Therapeutics WHWK Stock Holding History

Jeff Yass’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-31,300
Closed -$402K – 13657
2022
Q4 		$402K Sell
31,300
-40,300
-56% -$526K ﹤0.01% 8381
2022
Q3 		$1.01M Sell
71,600
-7,700
-10% -$101K ﹤0.01% 6612
2022
Q2 		$977K Buy
79,300
+25,100
+46% +$373K ﹤0.01% 6586
2022
Q1 		$920K Buy
+54,200
New +$1.04M ﹤0.01% 7336

Other funds holding WHWK

YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jeff Yass's WHWK Position: Q2 2026 in Review

Jeff Yass sold out of Whitehawk Therapeutics (WHWK) in Q2 2026, closing a stake of 203,465 shares — an estimated $702K sold.

Jeff Yass first reported a position in WHWK in Q4 2021 and held it in 14 quarters. The position peaked at $1.64M in Q1 2022. 78 funds tracked by Wall St. Rank hold WHWK as of Q2 2026.

  • Jeff Yass reported no remaining Whitehawk Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 203,465 Whitehawk Therapeutics shares in Q2 2026, an estimated $702K.
  • Jeff Yass first reported a position in Whitehawk Therapeutics in Q4 2021 and held it in 14 quarters.
  • Jeff Yass's Whitehawk Therapeutics position peaked at $1.64M in Q1 2022.
  • 78 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.